PLX-200

PLX-200 is an investigational oral small molecule drug originally developed to lower cholesterol and now being repurposed for the treatment of rare neurodegenerative diseases, including various forms of Batten disease (neuronal ceroid lipofuscinosis), globoid cell leukodystrophy (Krabbe disease), and Tay-Sachs disease. Developed by Polaryx Therapeutics, PLX-200 acts as a peroxisome proliferator-activated receptor alpha (PPARα) agonist and retinoid X receptor alpha (RXRα) agonist. By binding to RXRα and activating PPARα, it promotes the formation of a PPARα/RXRα heterodimer that enhances expression of genes involved in lysosome function—most notably increasing tripeptidyl peptidase 1 (TPP1) levels in neurons. This mechanism aims to restore lysosomal activity, reduce cellular waste accumulation, decrease inflammation, inhibit apoptosis (cell death), and provide neuroprotection. The drug has received orphan drug designation from the FDA for several rare diseases[2][3][5][7].

Other names

PLX 200PLX200PLX-200